Zoe K. Price

Metastasis of triple negative breast cancer is regulated by a targetable miR-342-E2F network

Victoria Kiriaki Arnet, Cameron N. Johnstone, Richard P. Redvers, Caroline A. Chambers et autres

Triple-negative breast cancer (TNBC) has a high incidence of metastasis and limited therapeutic options. Here, we identify a multimodal and targetable miR-342-E2F network that regulates metastatic outgrowth in TNBC. Through integrating clinical and experimental datasets, we uncover miR-342 as a suppressor of …

au (code pays fourni par la source)

P27 Minimising blood sampling by grouping gentamicin and c-reactive protein tests

Zoe K. Price, Aiisya Clark, Dr Temitope Lawal, Dr Nadia Nair

Aim National Institute for Health and Care Excellence (NICE) guideline NG195, ‘Neonatal infection: antibiotics for prevention and treatment’ 1, states that trough levels for the aminoglycoside antibiotic gentamicin should be known before the 2nd dose is administered, 36 hours after the first …

gb (code pays fourni par la source)

Proteomics analysis of serum extracellular vesicle identifies UCHL1 as a potential therapeutic target for high grade serous ovarian cancer

Noor A. Lokman, Anne M. Macpherson, A. Thompson, Zoe K. Price et autres

au, us (code pays fourni par la source)

Abstract A036: Protease-activated receptor F2R/PAR1 is a potential target for new diagnostic/prognostic and treatment applications for patients with ovarian cancer

Riya Khetan, Noor A. Lokman, Preethi Eldi, Zoe K. Price et autres

Abstract Background: Effective treatment of ovarian cancer is limited by late-stage detection and chemotherapy resistance. There is a clinical need for the discovery of novel molecular targets to enable the development of innovative theranostic approaches. We investigated the coagulation factor II receptor …

au (code pays fourni par la source)

Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer

Riya Khetan, Noor A. Lokman, Preethi Eldi, Zoe K. Price et autres

Effective treatment of ovarian cancer is limited by late-stage detection and chemotherapy resistance. There is a clinical need for the discovery of novel molecular targets to enable the development of innovative theranostic approaches. We investigated the coagulation factor II receptor/protease-activated receptor 1 …

au (code pays fourni par la source)

Identification of Proteins Associated with Ovarian Cancer Chemotherapy Resistance Using MALDI-MSI

Tannith M. Noye, Parul Mittal, Zoe K. Price, Annie Fewster et autres

Ovarian cancer is the most lethal gynecological cancer. Up to 75% of cases are high-grade serous ovarian cancer (HGSOC) that have high chemosensitivity to first-line platinum-based therapies. However, 75% of patients will become chemoresistant following relapse. The underlying mechanism for developing resistance …

au (code pays fourni par la source)

Identification of Sphingosine Kinase 1 as a Novel Protein Regulated by High Molecular Weight Hyaluronan in Ovarian Cancer

Zoe K. Price, Noor A. Lokman, Jessica Morrison, Sisanda N Mhlanga et autres

The effects of hyaluronan (HA) in cancer are widely studied; however, the role of different molecular weight HA is poorly understood. Identifying novel proteins regulated by different molecular weight HA may highlight novel therapeutic targets. Proteomics analysis was performed to identify novel …

au, jp (code pays fourni par la source)

Abstract 6320: CAR-T cells targeting LGR5: An effective treatment for chemotherapy resistant ovarian cancer

Wanqi Wang, Veronika Bandara, Noor A. Lokman, Zoe K. Price et autres

Abstract Ovarian cancer is the second leading cause of cancer-related mortality among gynaecological cancers in the Western world. CAR-T cell therapy is an adoptive immunotherapy used to treat some blood cancers. This study has investigated whether leucine-rich repeat-containing G protein-coupled receptor 5 …

au (code pays fourni par la source)

Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer

Zoe K. Price, Noor A. Lokman, Mai Sugiyama, Yoshihiro Koya et autres

Although the pro-tumorigenic functions of hyaluronan (HA) are well documented there is limited information on the effects and targets of different molecular weight HA. Here, we investigated the effects of 27 kDa, 183 kDa and 1000 kDa HA on ES-2 ovarian cancer …

au, jp (code pays fourni par la source)

Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer

Zoe K. Price, Noor A. Lokman, Mai Sugiyama, Yoshihiro Koya et autres

au, jp (code pays fourni par la source)

Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor suppressor and tumor promoting roles in ovarian cancer

Zoe K. Price, Noor A. Lokman, Mai Sugiyama, Yoshihiro Koya et autres

au, jp (code pays fourni par la source)

Pharmacological Inhibition of Membrane Signaling Mechanisms Reduces the Invasiveness of U87-MG and U251-MG Glioblastoma Cells In Vitro

Alanah Varricchio, Sidra Khan, Zoe K. Price, Rohan A. Davis et autres

Impairing the motility of glioblastoma multiforme (GBM) cells is a compelling goal for new approaches to manage this highly invasive and rapidly lethal human brain cancer. Work here characterized an array of pharmacological inhibitors of membrane ion and water channels, alone and …

au (code pays fourni par la source)